When considering staffing reductions, a fair and empathetic compensation program is imperative in the tight-knit biotech and pharma industries.

Leadership transition is an ongoing process. Here are four guiding points for boards and CEOs that former Pearl Meyer Chairman David Swinford suggested considering.

For biotech, the retention value of options is currently in jeopardy. Here are several key points to weigh if your company is considering strong action.

A changing talent landscape and numerous external influences may require the board to look closer at workforce pay.

How can provider organizations retain those still in their jobs and effectively recruit quality candidates? The answer may be market-based pay.

As companies grant more equity to more employees, the conversation about pay is also evolving.

The competition for experienced, effective director talent is fierce. Healthcare boards should consider board pay as a recruiting and retention tool.

Creating smooth transitions between incoming and outgoing directors is dependent on your compensation strategy and board policies.

There has never been a more critical time for boards and management teams to up their game when it comes to compensation communication.